SCHEMBL843784

SCHEMBL843784

O=C(O)c1cc2ncccc2s1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN3B O60391 1/20 0.57
GRIN1 Q05586 1/20 0.57
GRIN2C Q14957 1/20 0.57
BCL2L1 Q07817 1/20 0.53
NAMPT P43490 1/20 0.51
KDM4E B2RXH2 3/20 0.47
ALOX5 P09917 1/20 0.47
GPR35 Q9HC97 3/20 0.44
PLK4 O00444 1/20 0.42
AURKA O14965 1/20 0.42
DAPK3 O43293 1/20 0.42
CHEK2 O96017 1/20 0.42
CDK1 P06493 1/20 0.42
PIM1 P11309 1/20 0.42
PRKACA P17612 1/20 0.42
CDK2 P24941 1/20 0.42
MAPK9 P45984 1/20 0.42
CSNK1D P48730 1/20 0.42
GSK3A P49840 1/20 0.42
GSK3B P49841 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29365840 1.00 GRIN3B (0.57) GRIN3BGRIN1GRIN2CBCL2L1NAMPT
SCHEMBL3308576 0.98 GRIN3B (0.56) GRIN3BGRIN1GRIN2CBCL2L1NAMPT
SCHEMBL1217553 0.84 GRIN3B (0.56) GRIN3BGRIN1GRIN2CNAMPTALOX5
SCHEMBL31108975 0.84 GRIN3B (0.56) GRIN3BGRIN1GRIN2CNAMPTALOX5
SCHEMBL10650333 0.84 GRIN3B (0.52) GRIN3BGRIN1GRIN2CNAMPTALOX5
SCHEMBL843685 0.83 GRIN3B (0.52) GRIN3BGRIN1GRIN2CNAMPTKDM4E
SCHEMBL29368089 0.83 GRIN3B (0.52) GRIN3BGRIN1GRIN2CNAMPTKDM4E
Lithium Ion SCHEMBL3308570 0.83 GRIN3B (0.51) GRIN3BGRIN1GRIN2CBCL2L1NAMPT
SCHEMBL5775228 0.80 GRIN3B (0.49) GRIN3BGRIN1GRIN2CNAMPTKDM4E
SCHEMBL5776214 0.80 GRIN3B (0.59) GRIN3BGRIN1GRIN2CNAMPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1649857-A2 New use of glutamate antagonists for the treatment of cancer Ikonomidou, Hrissanthi (DE) 2006-04-26 EP claimed
US-20050054650-A1 Use of glutamate antagonists for the treatment of cancer IKONOMIDOU HRISSANTHI (DE) 2005-03-10 US claimed
EP-1124553-A1 NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER Ikonomidou, Hrissanthi (DE) 2001-08-22 EP claimed
EP-1002535-A1 New use of glutamate antagonists for the treatment of cancer Ikonomidou, Hrissanthi (DE) 2000-05-24 EP claimed
WO-2000024395-A1 NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER IKONOMIDOU HRISSANTHI (DE) 2000-05-04 WO claimed
JP-57042690-A None JP disclosed
JP-52010291-A None JP disclosed
EP-4635953-A1 PYRROLOPYRIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF Iregene Therapeutics Co., Ltd (CN) 2025-10-22 EP disclosed
WO-2025153045-A1 PYRIDOTHIOPHENE-2-CARBOXYLIC ACID DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF 上海拓界生物医药科技有限公司 2025-07-24 WO disclosed
US-20240383914-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE JANSSEN PHARMACEUTICA NV (BE) 2024-11-21 US disclosed
US-12065446-B2 Inhibitors of Bruton's tyrosine kinase and method of their use JANSSEN PHARMACEUTICA NV (BE) 2024-08-20 US disclosed
US-20240043446-A1 ANTHELMINTIC COMPOUNDS COMPRISING A THIENOPYRIDINE STRUCTURE INTERVET INC. (US) 2024-02-08 US disclosed
US-4079060-A Thienopyridine-carboxylic acid derivatives TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) 1978-03-14 US disclosed
JP-S5210291-A PROCESS FOR PREPARING THIENOPYRIDINE CARBOXYLIC ACID DERIVATIVES TAKEDA CHEM IND LTD 1977-01-26 JP disclosed
US-3997545-A Thienopyridine-carboxylic acid derivatives TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) 1976-12-14 US disclosed
US-3997545-A Thienopyridine-carboxylic acid derivatives TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) 1976-12-14 US disclosed
US-3997545-A Thienopyridine-carboxylic acid derivatives TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) 1976-12-14 US disclosed
US-3951989-A Thienopyridine-carboxylic acid derivatives TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) 1976-04-20 US disclosed
US-3951989-A Thienopyridine-carboxylic acid derivatives TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) 1976-04-20 US disclosed
US-3951989-A Thienopyridine-carboxylic acid derivatives TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) 1976-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12065446-B2 Inhibitors of Bruton's tyrosine kinase and method of their use ABL1, BTK, LYN GRIN3B 1463/4885GRIN1 1726/4885GRIN2C 1758/4885
US-20240383914-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE ABL1, BTK, MYLK2 GRIN3B 1581/4885GRIN1 1859/4885GRIN2C 1627/4885
US-20240043446-A1 ANTHELMINTIC COMPOUNDS COMPRISING A THIENOPYRIDINE STRUCTURE DHODH, NISCH, DDT GRIN3B 3755/4885GRIN1 3315/4885GRIN2C 2101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.